After years of delay, Roche takes one of Spark’s hemophilia gene therapies into PhIII, drops another
As Roche finally puts one gene therapy for hemophilia A into Phase III, it’s discarding another.
Roche disclosed the removal of RG6358, or SPK-8016, in its second quarter earnings presentation, where it also noted that a Phase III trial of RG6357, or SPK-8011, has been initiated. The company is aiming to open enrollment for the study, which will be called Keystone1, later this year, a spokesperson confirmed in an email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
